Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA:688443)

China flag China · Delayed Price · Currency is CNY
22.22
+0.12 (0.54%)
At close: Jul 31, 2026
Market Cap8.15B -33.5%
Revenue (ttm)277.82M +452.9%
Net Income-564.33M
EPS-1.54
Shares Out 366.68M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,239,463
Open22.53
Previous Close22.10
Day's Range22.22 - 22.90
52-Week Range20.07 - 37.88
Beta0.63
Analystsn/a
Price Targetn/a
Earnings DateAug 31, 2026

About SHA:688443

Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondyloarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic lupus erythematosus; GR2002 an anti-TSLP bispecific antibody; WM1R3, a family receptor bispecific antibody; GR2001, a monoclonal antibody; GR2201, a m... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 984
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688443
Full Company Profile

Financial Performance

In 2025, SHA:688443's revenue was 230.73 million, an increase of 666.66% compared to the previous year's 30.09 million. Losses were -535.65 million, -32.81% less than in 2024.

Financial Statements